We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fampridine- PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.
- Authors
Leussink, Verena‐Isabell; Stettner, Mark; Warnke, Clemens; Hartung, Hans‐Peter
- Abstract
Fampridine- PR is a voltage-gated potassium channel inhibitor potentially improving nerve conduction in demyelinated axons. Based on its established clinical efficacy in patients with demyelination in the central nervous system, we assessed if fampridine- PR is also effective in patients with inflammatory demyelination of the peripheral nerve. In this small open-label study, 10 patients with chronic inflammatory demyelinating polyradiculoneuropathy ( CIDP) were treated with fampridine- PR 10 mg BID for 28 days and assessed clinically as well as by nerve conduction studies. In this study, Fampridine- PR failed to improve CIDP based on clinical measures and nerve conduction studies. Our findings suggest that Fampridine- PR appears to be ineffective in demyelinating polyneuropathies. These observations may indicate a more complex mode of action beyond improving action potential conduction in demyelinated axons.
- Subjects
CONTROLLED release drugs; AMINOPYRIDINES; CHRONIC diseases; ELECTROPHYSIOLOGY; NEURAL conduction; HEALTH outcome assessment; GUILLAIN-Barre syndrome; TREATMENT effectiveness; THERAPEUTICS
- Publication
Journal of the Peripheral Nervous System, 2016, Vol 21, Issue 2, p85
- ISSN
1085-9489
- Publication type
Article
- DOI
10.1111/jns.12169